Today before the opening bell, Actinium announced that it has engaged the investor relations services of MissionIR. Through its network of investor-oriented sites and full suite of investor awareness services, MissionIR broadens the influence of publicly traded companies and enhances their ability to attract growth capital as well as improve shareholder value.
"Actinium is wrapping up a year of tremendous progress in the development of its cancer treatment candidates, and is on the cusp of initiating additional clinical trials," stated Sherri Franklin, Director of Marketing at MissionIR. "MissionIR is pleased to partner with the Company as it starts off a new year of advances with a firm stance and high potential in the biotech industry."
"We're moving closer to the commercialization of our cancer drugs, and want to increase visibility in the investment community and enhance communication with our existing shareholders along the way," Dr. Kaushik J. Dave, President and CEO of Actinium, stated. "Engaging a full-service investor relations firm will help us develop and implement a strategic investor relations campaign to reach this goal. MissionIR is providing a much-needed service in the small-cap markets."
Actinium is a New York-based pharmaceuticals company that is developing innovative immunotherapeutic solutions for treatment of advanced cancers. Specifically, the company harnesses its proprietary platform for the therapeutic utilization of alpha particle emitting actinium-225 and bismuth-213 radiopharmaceuticals, in association with monoclonal antibodies, for development of alpha particle immunotherapeutics.
Actinium intends to develop its cancer treatment products through clinical trials and then intends to partner each drug for completion of development and commercialization with an appropriate third party. In working toward this objective, the company aims to increase brand awareness.
For more information about Actinium, its developments, and its progress, please visit: actiniumpharmaceuticals.com
MissionIR provides investor relations services to publicly traded companies in exchange for compensation. This article may be part of our efforts to widen a client's exposure. To read our full disclaimer, visit http://disclaimer.missionir.com